Consistent with these studies, our study found that upregulation of kallistatin caused an increase in cells in the G1 phase and a decrease in cells in the G2 phase and inhibited the growth of ovarian cancer cells in vitro and in vivo. The gene discussed is SERPINA4; the disease is ovarian carcinoma.